Weekly Digest - October 2026

Weekly Digest - October 2026

12 October 2026: Iza-Bren combination with radiotherapy received NMPA clinical trial approval for HNSCC

  • Sichuan Biokin Pharmaceutical announced that China’s NMPA has approved the clinical trial application for Iza-bren in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors, expanding the ADC’s development into locally advanced disease
  • The approval authorizes clinical evaluation of Iza-bren with radiotherapy. Iza-bren has received NMPA marketing approval for recurrent/metastatic nasopharyngeal carcinoma and esophageal squamous cell carcinoma, while its NDA for triple-negative breast cancer has been accepted for review
  • The program addresses the unmet need for improved treatment options for patients with locally advanced unresectable HNSCC, where achieving durable locoregional disease control remains challenging. Combining Iza-bren with radiotherapy provides an opportunity to evaluate whether targeted cytotoxic drug delivery alongside radiation can improve treatment outcomes
  • Iza-bren is an EGFR×HER3 bispecific ADC designed to engage both receptors and deliver a cytotoxic payload to tumor cells expressing either or both targets. Dual targeting may broaden tumor recognition and support internalization, providing a rationale for evaluation alongside radiotherapy
  • Strategically, the trial expands Iza-bren beyond recurrent or metastatic disease into a potentially earlier, locally advanced treatment setting, broadening its development across tumor types and treatment approaches. Alongside its existing approvals and ongoing programs in breast and lung cancers, the radiotherapy combination further diversifies Biokin’s development strategy for its lead bispecific ADC

For full story click  here

Share this